Answers are grounded in this paper and cite their sources.
Two studies in this issue of the Journal 1,2 describe a new drug, GDC-0449, that inhibits the hedgehog signaling pathway. This pathway orchestrates numerous processes throughout embryogenesis, and although the pathway seems inactive or dispensable in most adult tissues, it becomes reactivated in a wide range of cancers.3 For this reason, blockade of the hedgehog pathway could yield a greater degree of selectivity and fewer side effects in the treatment of cancer than conventional chemotherapy. The preliminary data in these two studies raise hopes that this may indeed be the case.In the phase 1 study by Von Hoff et . . .
No takes yet. Share an insight, caveat, or question.
Dlugosz et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: